Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome

American Journal of Transplantation

Volumn 9, Issue 11, 2009, Pages 2644-2645

  Chatelet, V ^a   Fremeaux Bacchi V ^b   Lobbedez, T ^a   Ficheux, M ^a   De Ligny, B Hurault ^a  

^a CHU Clemenceau   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB;

ADULT; BLOOD TRANSFUSION; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LETTER; LONG TERM CARE; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; SEPTICEMIA; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; RECURRENCE;

EID: 70350130833     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02817.x     Document Type: Letter

References (3)

1. Hillmen P, Hall C, Marsh JCW et al. Effect of Eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 350 : 552 559.
2. Nürnberger J, Witzke O, Opazo Saez A et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 : 542 544.
3. Frémeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical haemolytic uremic syndrome. Blood 2008 112 : 4948 4952.